Insmed Reports Third-Quarter 2025 Financial Results and FDA Approval for BRINSUPRI

Details

The company raised its full-year 2025 global ARIKAYCE revenue guidance to a range of $420 million to $430 million. On October 30, 2025, the FDA approved BRINSUPRI (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis. Insmed expects commercial launches in the EU, UK, and Japan in 2026, pending regulatory approval. The company also provided updates on its clinical trial programs and research efforts.

Items reported

About Insmed Inc.

Insmed Inc. is a biopharmaceutical company dedicated to enhancing the lives of patients with rare diseases. The company's primary focus is on the development and commercialization of treatments for serious and rare disorders, particularly in the fields of pulmonology and infectious diseases. One of Insmed's noteworthy products is Arikayce, an inhaled antibiotic that addresses specific pulmonary infections often affecting patients with underlying lung conditions. Insmed Inc. also undertakes robust research and development efforts to boost its pipeline of potential therapies, aiming to address unmet medical needs. Operating within the broader healthcare sector, Insmed is a key player in the biopharmaceutical landscape, driven by innovation and scientific research. The company’s continued advancements and strategic collaborations underscore its commitment to elevating patient care and expanding treatment options for rare disease patients. This aligns Insmed as a significant entity in the realm of specialized healthcare solutions, reflecting its impact on the biopharmaceutical market.